ArticleFrontiers in cellular and infection microbiology2025
Population structure and emergence of resistance to new and repurposed drugs in XDR-TB: insights from a 10-year genomic study in the Western Cape, South Africa review.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Resistance to Linezolid and Pretomanid in the Era of Modern Drug-Resistant Tuberculosis Treatment in South Africa: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Mixed-strain infection and heteroresistance in drug-resistant tuberculosis: insights from a whole-genome sequencing pilot.Frontiers in epidemiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extensively drug-resistant tuberculosis (XDR-TB) is a global health threat, being expensive and difficult to treat, with high mortality rates. The Western Cape Province (WCP), South Africa, has a particularly high burden of XDR-TB (>800 cases in the past ten years). Drug resistance genotypes and transmission present substantial regional variability. Thus, a better understanding of genetic diversity, clustering and the factors related to transmission can aid in prioritising resources to effectively target high-risk populations and regions that are disproportionately affected. We describe genetic diversity, drug resistance profiles and identify potential factors associated with the spread of XDR-TB strains collected in the WCP. Methods: We included 729 XDR-TB samples (one per patient), identified through routine diagnosis spanning 2010 to 2019, from six healthcare districts (HCDs) in the WCP. Genomic DNA from cultured isolates was sequenced using the Illumina platform. Sequences were analysed for strain type, drug resistance mutations, and genomic clustering using the TBProfiler and MTBseq pipelines. We conducted logistic regression analysis to identify potential factors associated with genomic traits related to the spread of XDR-TB strains. Results: Of the 729 XDR-TB strains, sublineage 2.2.2 (Atypical Beijing: n=378, 58.79%) strains were predominant, followed by Sublineage 2.2.1 (Typical Beijing: n=260, 40.43%). Atypical Beijing strains were more likely to cluster than Typical Beijing strains. Most of the clusters were small, with a few large and very large clusters, and the strains within very large clusters (primarily Atypical Beijing) were more likely to be found within Cape Town Metropole, Cape Winelands and Garden Route HCDs. Certain Atypical Beijing strains were found resistant to new and repurposed drugs recently introduced in the WHO treatment guidelines and clustered, indicating potential transmission. Conclusions: Near-untreatable Atypical Beijing strains are prevalent in the WCP. Hence, hotspot areas for clustering in Cape Town Metropole, Cape Winelands and Garden Route HCDs should be prioritised for targeted intervention to prevent ongoing XDR-TB transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.